DBV Fundamental Analysis - DBV TECHNOLOGIES SA

Name: DBV TECHNOLOGIES SA (DBV) Stock
Brand: DBV TECHNOLOGIES SA
Rating: 6.5 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to DBV. DBV was compared to 76 industry peers in the Biotechnology industry. DBV has a bad profitability rating. Also its financial health evaluation is rather negative. DBV is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

DBV had negative earnings in the past year.

In the past year DBV has reported a negative cash flow from operations.

In the past 5 years DBV always reported negative net income.

DBV had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

DBV's Return On Assets of -85.56% is on the low side compared to the rest of the industry. DBV is outperformed by 71.05% of its industry peers.

With a Return On Equity value of -142.22%, DBV perfoms like the industry average, outperforming 40.79% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-85.56%
ROE	-142.22%
ROIC	N/A

ROA(3y)-84.27%

ROA(5y)-75.7%

ROE(3y)-172.64%

ROE(5y)-138.93%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 91.34%, DBV belongs to the top of the industry, outperforming 85.53% of the companies in the same industry.

DBV's Gross Margin has declined in the last couple of years.

DBV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	91.34%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.75%

GM growth 5Y-2.02%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

DBV does not have a ROIC to compare to the WACC, probably because it is not profitable.

DBV has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, DBV has more shares outstanding

DBV has a worse debt/assets ratio than last year.

2.2 Solvency

DBV has an Altman-Z score of -2.66. This is a bad value and indicates that DBV is not financially healthy and even has some risk of bankruptcy.

DBV's Altman-Z score of -2.66 is on the low side compared to the rest of the industry. DBV is outperformed by 63.16% of its industry peers.

DBV has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.

The Debt to Equity ratio of DBV (0.08) is better than 63.16% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Altman-Z	-2.66

ROIC/WACCN/A

WACC7.8%

2.3 Liquidity

A Current Ratio of 2.45 indicates that DBV has no problem at all paying its short term obligations.

DBV has a Current ratio of 2.45. This is comparable to the rest of the industry: DBV outperforms 53.95% of its industry peers.

A Quick Ratio of 2.45 indicates that DBV has no problem at all paying its short term obligations.

DBV has a Quick ratio (2.45) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.45
Quick Ratio	2.45

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

DBV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.83%.

DBV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -72.49%.

The Revenue for DBV have been decreasing by -22.35% on average. This is quite bad

EPS 1Y (TTM)-22.83%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%8.82%

Revenue 1Y (TTM)-72.49%

Revenue growth 3Y-10.07%

Revenue growth 5Y-22.35%

Sales Q2Q%26.18%

3.2 Future

The Earnings Per Share is expected to grow by 23.50% on average over the next years. This is a very strong growth

Based on estimates for the next years, DBV will show a very strong growth in Revenue. The Revenue will grow by 146.91% on average per year.

EPS Next Y1.69%

EPS Next 2Y37.64%

EPS Next 3Y23.5%

EPS Next 5YN/A

Revenue Next Year2930.57%

Revenue Next 2Y1762.26%

Revenue Next 3Y277.96%

Revenue Next 5Y146.91%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

DBV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DBV. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

DBV's earnings are expected to grow with 23.50% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y37.64%

EPS Next 3Y23.5%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for DBV!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

DBV TECHNOLOGIES SA

EPA:DBV (11/3/2025, 11:03:32 AM)

2.515

-0.11 (-4.19%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)07-29 2025-07-29/amc

Earnings (Next)03-23 2026-03-23/amc

Inst Owners53.95%

Inst Owner ChangeN/A

Ins Owners0.06%

Ins Owner ChangeN/A

Market Cap68.84M

Revenue(TTM)3.80M

Net Income(TTM)-122551000

Analysts80

Price Target3.96 (57.46%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)6.65%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-29.19%

Revenue NY rev (1m)0%

Revenue NY rev (3m)2.38%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	20.93
P/FCF	N/A
P/OCF	N/A
P/B	0.92
P/tB	0.92
EV/EBITDA	N/A

EPS(TTM)-0.98

EYN/A

EPS(NY)-0.09

Fwd EYN/A

FCF(TTM)-2.79

FCFYN/A

OCF(TTM)-2.78

OCFYN/A

SpS0.12

BVpS2.72

TBVpS2.72

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-85.56%
ROE	-142.22%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	91.34%
FCFM	N/A

ROA(3y)-84.27%

ROA(5y)-75.7%

ROE(3y)-172.64%

ROE(5y)-138.93%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.75%

GM growth 5Y-2.02%

F-Score2

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	42.61%
Cap/Sales	8.26%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.45
Quick Ratio	2.45
Altman-Z	-2.66

F-Score2

WACC7.8%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)25.42%

Cap/Sales(5y)23.37%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-22.83%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%8.82%

EPS Next Y1.69%

EPS Next 2Y37.64%

EPS Next 3Y23.5%

EPS Next 5YN/A

Revenue 1Y (TTM)-72.49%

Revenue growth 3Y-10.07%

Revenue growth 5Y-22.35%

Sales Q2Q%26.18%

Revenue Next Year2930.57%

Revenue Next 2Y1762.26%

Revenue Next 3Y277.96%

Revenue Next 5Y146.91%

EBIT growth 1Y-31.72%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year11.07%

EBIT Next 3Y16.69%

EBIT Next 5YN/A

FCF growth 1Y0.85%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y0.45%

OCF growth 3YN/A

OCF growth 5YN/A

DBV TECHNOLOGIES SA / DBV.PA FAQ

What is the fundamental rating for DBV stock?

ChartMill assigns a fundamental rating of 2 / 10 to DBV.PA.

Can you provide the valuation status for DBV TECHNOLOGIES SA?

ChartMill assigns a valuation rating of 1 / 10 to DBV TECHNOLOGIES SA (DBV.PA). This can be considered as Overvalued.

What is the profitability of DBV stock?

DBV TECHNOLOGIES SA (DBV.PA) has a profitability rating of 1 / 10.

What is the expected EPS growth for DBV TECHNOLOGIES SA (DBV.PA) stock?

The Earnings per Share (EPS) of DBV TECHNOLOGIES SA (DBV.PA) is expected to grow by 1.69% in the next year.

DBV TECHNOLOGIES SA (DBV.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

DBV TECHNOLOGIES SA / DBV.PA FAQ

What is the fundamental rating for DBV stock?

Can you provide the valuation status for DBV TECHNOLOGIES SA?

What is the profitability of DBV stock?

What is the expected EPS growth for DBV TECHNOLOGIES SA (DBV.PA) stock?